Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells

Molecular Pharmacology

Volumn 81, Issue 5, 2012, Pages 701-709

  Tan, Shinta ^a   Hougardy, Brigitte M T ^a   Meersma, Gert J ^a   Schaap, Bessel ^a   De Vries, Elisabeth G E ^a   Van Der Zee, Ate G J ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIBODY; ONCOPROTEIN; PROTEIN E16; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IRRADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HELA CELLS; HUMANS; ONCOGENE PROTEINS, VIRAL; RECEPTORS, DEATH DOMAIN; REPRESSOR PROTEINS; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84859945722     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.076539     Document Type: Article

References (40)

1. Aguilar-Lemarroy A, Kirchhoff S, Whitaker N, Gariglio P, zur Hausen H, Krammer PH, and Rösl F (2001) Differential sensitivity of human papillomavirus type 16(+) and type 18(+) cervical carcinoma cells to CD95-mediated apoptosis. Int J Cancer 93:823-831. (Pubitemid 32756752)
2. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, and Sorger PK (2008) Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 30:11-25. (Pubitemid 351470145)
3. Amm HM, Zhou T, Steg AD, Kuo H, Li Y, and Buchsbaum DJ (2011) Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Mol Cancer Res 9:403-417.
4. Ashkenazi A, Holland P, and Eckhardt SG (2008) Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26:3621-3630.
5. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, and Weissberg P (1998) Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290-293. (Pubitemid 28487200)
6. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, and Hoppe-Seyler F (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus- positive cancer cells. Oncogene 22:5938-5945. (Pubitemid 37175872)
7. Chang JT, Kuo TF, Chen YJ, Chiu CC, Lu YC, Li HF, Shen CR, and Cheng AJ (2010) Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18- infected cervical cancers. Cancer Gene Ther 17:827-836.
8. Eaton S, Wiktor P, Thirstrup D, Lake D, and Nagaraj VJ (2011) Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes. Biochem Biophys Res Commun 405:1-6.
9. Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, Tungteakkhun SS, Williams K, and Duerksen-Hughes PJ (2007) The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 81:4116-4129. (Pubitemid 46586906)
10. Filippova M, Parkhurst L, and Duerksen-Hughes PJ (2004) The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 279:25729-25744. (Pubitemid 38756837)
11. Guan B, Yue P, Clayman GL, and Sun SY (2001) Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 188:98-105. (Pubitemid 32476500)
12. Herrington CS, de Angelis M, Evans MF, Troncone G, and McGee JO (1992) Detection of high risk human papillomavirus in routine cervical smears: strategy for screening. J Clin Pathol 45:385-390.
13. Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, and de Jong S (2006) Proteasome inhibitor MG132 sensitizes HPVpositive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 118:1892-1900.
14. Hougardy BM, Reesink-Peters N, van den Heuvel FA, ten Hoor KA, Hollema H, de Vries EG, de Jong S, and van der Zee AG (2008) A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer 123: 1457-1465.
15. Hougardy BM, van der Zee AG, van den Heuvel FA, Timmer T, de Vries EG, and de Jong S (2005) Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid. Gynecol Oncol 97:353-364. (Pubitemid 40614875)
16. Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, and Berenson J (2010) The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 10:28-43.
17. Jiang M and Milner J (2002) Selective silencing of viral gene expression in HPVpositive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21:6041-6048.
18. Jung HS, Erkin OC, Kwon MJ, Kim SH, Jung JI, Oh YK, Her SW, Ju W, Choi YL, Song SY, et al. (2012) The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int J Cancer 130:1925-1936.
19. Kadaja M, Isok-Paas H, Laos T, Ustav E, and Ustav M (2009) Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog 5:e1000397.
20. Koivusalo R, Krausz E, Helenius H, and Hietanen S (2005) Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 68:372-382. (Pubitemid 41058301)
21. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, and de Jong S (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 120:3594-3605.
22. Liu WL, Green N, Seymour LW, and Stevenson M (2009) Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. Cancer Gene Ther 16:764-775.
23. Liu X, Yue P, Khuri FR, and Sun SY (2004) p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64:5078-5083. (Pubitemid 39006522)
24. Mahalingam D, Szegezdi E, Keane M, de Jong S, and Samali A (2009) TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35:280-288.
25. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, and Huh K (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451-11460. (Pubitemid 39390733)
26. Parkin DM, Bray F, Ferlay J, and Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. (Pubitemid 40372904)
27. Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, and de Jong S (2010) Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 1805:123-140.
28. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, and McMillan NA (2005) RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 68:1311-1319. (Pubitemid 41539987)
29. Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, and van der Zee AG (2005) Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96:705-713. (Pubitemid 40255490)
30. Salvesen GS and Duckett CS (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410. (Pubitemid 34685698)
31. Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J, Xu G, Meng L, Lu Y, Wang S, et al. (2008) RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 13:273-281.
32. Spierings DC, de Vries EG, Stel AJ, te Rietstap N, Vellenga E, and de Jong S (2004) Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene 23:4862-4872. (Pubitemid 38937046)
33. Tan S, de Vries EG, van der Zee AG, and de Jong S (2012) Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 12:170-184.
34. Tang S, Tao M, McCoy JP Jr, and Zheng ZM (2006) The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol 80:4249-4263.
35. Vogt M, Butz K, Dymalla S, Semzow J, and Hoppe-Seyler F (2006) Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 25:4009-4015. (Pubitemid 44024863)
36. Yamato K, Fen J, Kobuchi H, Nasu Y, Yamada T, Nishihara T, Ikeda Y, Kizaki M, and Yoshinouchi M (2006) Induction of cell death in human papillomavirus 18- positive cervical cancer cells by E6 siRNA. Cancer Gene Ther 13:234-241. (Pubitemid 43255760)
37. Yamato K, Yamada T, Kizaki M, Ui-Tei K, Natori Y, Fujino M, Nishihara T, Ikeda Y, Nasu Y, Saigo K, et al. (2008) New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther 15:140-153. (Pubitemid 351240669)
38. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, and Yamato K (2003) In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 8:762-768. (Pubitemid 37527451)
39. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, and Haupt Y (2009) Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 219:3-15.
40. zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690-698.